Frazier Healthcare Partners

Managing Partner Nader Naini leads the firm alongside a partnership group that includes Nathan Every, Ben Magnano, Brian Morfitt, and Christina Reszka. Each partner takes board-level responsibility for specific portfolio companies, and the firm's website lists over ten named partners actively managing investments. Investment decisions are made by the partnership collectively.

Frazier operates two independent investment teams. The Healthcare Partners group focuses on growth buyouts of profitable middle-market US healthcare companies across services, products, and technology. The Life Sciences team invests in private and publicly traded biopharmaceutical companies developing innovative drugs. The separation lets each team run its own sourcing, diligence, and portfolio management process while sharing the Frazier brand.

Frazier does not publish standardized check sizes. The firm's middle-market buyout practice targets profitable healthcare companies, with portfolio company revenues typically in the $20 million to $200 million range at entry. The Life Sciences group invests across stages from preclinical to commercial-stage biopharma companies, including participation in public PIPEs and follow-on financings.

Frazier does not publish a negative sector list. Its portfolio coverage suggests the firm avoids acute-care hospital operations and pure-play insurance underwriting, focusing instead on outsourced provider services, pharma services, medical devices, healthcare IT, and specialty pharmacy. The firm has not disclosed investments in dental practice management or veterinary services.

The firm relies on a 30-year network built through repeated transactions with healthcare founders, operators, and intermediaries. Its sector-dedicated partnership model means senior partners spend their full time within healthcare niches — pharma services, provider platforms, or medical products — rather than cross-sector generalist sourcing. This domain density generates off-market and limited-process opportunities, particularly in founder-owned healthcare businesses seeking a knowledgeable partner.

Frazier invests out of its own committed capital and has not disclosed raising a fund of funds or making LP commitments to external GPs. The firm's model is direct investment into operating companies, whether as a control equity owner in the Healthcare Partners strategy or as a minority and public-market investor in the Life Sciences strategy.

Frazier typically leads or co-leads its middle-market investments and seats its own partners on portfolio company boards. In the Life Sciences strategy, the firm regularly co-invests alongside other venture and crossover funds in syndicated biotech financings, consistent with standard practice in that asset class. The firm has not publicly disclosed a formal co-investment program for its LP base.